Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genetics and Genomics, |
RCV001270007 | SCV001450422 | pathogenic | not provided | 2019-05-13 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001270007 | SCV001714492 | likely pathogenic | not provided | 2019-08-26 | criteria provided, single submitter | clinical testing | PVS1, PM2 |
Labcorp Genetics |
RCV003120521 | SCV003787002 | pathogenic | Galactosylceramide beta-galactosidase deficiency | 2022-08-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 988571). This variant is also known as c.293insT. This premature translational stop signal has been observed in individual(s) with Krabbe disease (PMID: 31240153). This variant is present in population databases (rs757799254, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Leu98Phefs*8) in the GALC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GALC are known to be pathogenic (PMID: 7437911, 9272171, 16607461). |